Investigating the effect of empagliflozin and melijent in chronic kidney failure patients

Comparison of the effect of empagliflozin and metformin with Melijent and metformin in chronic kidney failure patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230607058409N1

Enrollment

150

Registered

2023-06-15

Start date

2023-06-22

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic patients. Type 2 diabetes mellitus with kidney complications

Interventions

Intervention 1: When the researcher ensures that the candidate is suitable for entering the study according to all the inclusion and non-entry criteria, the candidate will be placed in one of the foll

To ensure acceptance and safety, the drug will be prescribed by an internal specialist. Intervention group one: administration of metformin + empagliflozin Patients in both groups will be followed up

To ensure acceptance and safety, the drug will be prescribed by an internal specialist. Intervention group one: administration of metformin + empagliflozin, intervention group two (active control): a

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: -Patients with over 20mL/min/1.73m2 (calculated by MDRD formula) in the first visit Patient over 18 years old patients -Patients with less 60 ml /min/1.73m2 (calculated by MDRD formula) in the first visit

Exclusion criteria

Exclusion criteria: Class four congestive heart failure Recurrent urinary infection Myocardial infarction, stroke, transient ischemic attack

Design outcomes

Primary

Measure	Time frame
1) Examination of renal function (GFR). Timepoint: The effect of improving the renal function of GFR at the beginning of the study (before the start of the intervention) 3 and 6 months after the start of the drugs. Method of measurement: 140-Ageweight/ creatinine plasma72.;The amount of proteinuria. Timepoint: The amount of proteinuria at the beginning of the study (before the start of the intervention) 3 and 6 months after the start of the drugs. Method of measurement: 24-hour proteinuria (mg/dl).	—

Measure

Time frame

1) Examination of renal function (GFR). Timepoint: The effect of improving the renal function of GFR at the beginning of the study (before the start of the intervention) 3 and 6 months after the start of the drugs. Method of measurement: 140-Age*weight/ creatinine plasma*72.;The amount of proteinuria. Timepoint: The amount of proteinuria at the beginning of the study (before the start of the intervention) 3 and 6 months after the start of the drugs. Method of measurement: 24-hour proteinuria (mg/dl).

—

Secondary

Measure	Time frame
Blood pressure. Timepoint: Blood pressure at the beginning of the study (before the start of the intervention) 3 and 6 months after the start of the drugs. Method of measurement: Mercury pressure gauge.;Fasting sugar. Timepoint: Fasting blood sugar levels at the beginning of the study (before the start of the intervention) 3 and 6 months after the start of the drugs. Method of measurement: Fasting blood sugar test (mg/dl).	—

Measure

Time frame

Blood pressure. Timepoint: Blood pressure at the beginning of the study (before the start of the intervention) 3 and 6 months after the start of the drugs. Method of measurement: Mercury pressure gauge.;Fasting sugar. Timepoint: Fasting blood sugar levels at the beginning of the study (before the start of the intervention) 3 and 6 months after the start of the drugs. Method of measurement: Fasting blood sugar test (mg/dl).

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactreza zeinabadi noghabi

Shahid Beheshti University of Medical Sciences

rezaappleapp@gmail.com+98 915 156 2940

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026